Anthrax is one of the deadly infectious disease as documented in the CDC website. In spite of the availability
of appropriate antimicrobial agents, the mortality related with the anthrax remains high. The pathogenicity of B.anthracis
is mainly accredited to the two foremost components: toxins and capsule. Virulence component of B.anthracis includes
protective antigen (PA) which plays a vital role in pathogenesis, virulence protein edema factor (EF) and lethal factor
(LF). This search for novel therapeutic strategies that attack the proteins involved in the pathogenesis of anthrax and may
potentially supplement antimicrobials being investigated. Currently, extensive attempts are in progress to develop novel
helpful therapies to all of the virulence components: lethal factor, protective antigen, edema factor and the capsule of B.
anthracis. This review discusses the potential anthrax therapeutic, prophylactic measures and diagnostic applications
based on recent patents’ prospects.
Keywords: Antibodies, anthrax toxins, Bacillus anthracis, ethal toxin, furin-like protease, protective antigen, plasmids, therapeutics,
Rights & PermissionsPrintExport